Clinical trial NCT06933797: Evaluation of the Potential Effects of LRP5 and Tph1 in the Pathogenesis of Periodontal Disease Individuals With Stage III Grade B Periodontitis
Official title: Evaluation of the Changes in LRP5 and TPH1 Levels Due to Periodontal Inflammation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontal Disease
Periodontitis (Stage 3)
Periodontitis Stage III
Keywords: Low-density lipoprotein receptor-associated protein 5
Tryptophan Hydroxylase 1
Periodontitis
Lead sponsor: Ankara University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2025-04-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consisted of patients with stage III periodontitis and periodontally healthy patients admitted to Ankara University Faculty of Dentistry Clinic.

Brief summary: Objectives: The aim of this study was to determine the changes in LRP5 and TPH1 levels in serum and saliva samples due to periodontal inflammation and to evaluate the relationship between these values and clinical periodontal parameters.

Methods: Saliva and serum samples were collected from 20 systemically healthy patients with Stage III periodontitis and 20 periodontally healthy control individuals. Salivary and serum LRP5 and TPH1 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters, including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL), were recorded.


Eligibility criteria: Inclusion Criteria:

* \>18 years old,
* At least 16 permanent teeth except 3rd molars,
* Individuals who do not use orthodontic appliances,
* Individuals who are not pregnant or lactating,
* Individuals without any systemic disease that may affect periodontal health,
* Systemically healthy individuals,
* Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have not received periodontal treatment in the last 1 year

Exclusion Criteria:

* Pregnant/lactating individuals,
* Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have undergone periodontal treatment in the last 1 year,
* Individuals with psychiatric illness,
* Individuals with any oral infection,
* Individuals with \<16 teeth, excluding molars,
* Individuals with alcohol dependence,
* Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
* Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Primary outcomes:
measure: LRP5
timeFrame: 1 month
measure: TPH1
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University, Faculty of Dentistry,
state: Yenimahalle
Study officials:
References:
citation: Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008 Nov 28;135(5):825-37. doi: 10.1016/j.cell.2008.09.059.
citation: Jiang H, Xi Y, Jiang Q, Dai W, Qin X, Zhang J, Jiang Z, Yang G, Chen Q. LRP5 Down-Regulation Exacerbates Inflammation and Alveolar Bone Loss in Periodontitis by Inhibiting PI3K/c-FOS Signalling. J Clin Periodontol. 2025 Apr;52(4):637-650. doi: 10.1111/jcpe.14112. Epub 2025 Jan 21.